Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GNLXthis companyGenelux Corporation	$2.07	-5.07×	14.04×	20,261.21×	-5.02×	-100.5%	-7075.0%	-415175.0%	-401812.5%	-278.5%	-251.1%	-16.3%	0.15×	0.12×	0×	2.43×	0.0%	2	-14.51	1	C-
ALDXAldeyra The	$0.62	-9.25×	7.03×	0×	-8.1×	40.2%	0.0%	0.0%	0.0%	-76.5%	-59.0%	-10.7%	0.35×	1.72×	-18.51×	2.58×	0.0%	1	-15.37	3	B
CADLCandel Therapeutics, Inc.	$9.60	-7.85×	5.76×	0×	-5.15×	-76.1%	0.0%	0.0%	0.0%	-73.5%	-41.4%	-13.0%	0.04×	3.35×	-22.78×	13.31×	0.0%	2	3.11	1	C-
CTNMContineum Therapeutics, Inc.	$10.47	-5.27×	1.21×	0×	-3.68×	-76.3%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	17.28	2	C+
LXEOLexeo Therapeutics, Inc. Common Stock	$3.18	-5.34×	2.16×	0×	-4.89×	-70.2%	0.0%	0.0%	0.0%	-40.5%	-42.9%	-18.6%	0.03×	0.56×	-530.37×	11.21×	0.0%	1	4.66	2	B-
LYELLyell Immunopharma, Inc.	$16.12	-1.92×	2.12×	14,614.52×	-1.97×	-97.9%	-31952.8%	-566038.9%	-762355.6%	-110.6%	-68.0%	-28.7%	0.21×	0.03×	0×	5.28×	0.0%	1	-8.56	2	C+
Peer median	—	-5.34×	2.16×	0×	-4.89×	-76.1%	0.0%	0.0%	0.0%	-73.5%	-42.9%	-17.5%	0.04×	0.99×	-18.51×	11.21×	0.0%	1	3.11	2	—